Literature DB >> 22493755

Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria.

Victoria K Pam1, Juliet U Akpan, Oyinlola O Oduyebo, Francisca O Nwaokorie, Muinah A Fowora, Rita O Oladele, Folasade T Ogunsola, Stella I Smith.   

Abstract

Fluconazole resistance is an important type of resistance in Candida because in most countries, fluconazole is the drug of choice for vulvovaginal candidiasis. Candida species resist fluconazole by various mechanisms but there is paucity of data on these in our environment. Such mechanisms include among others, over-expression of the ERG11 gene, which codes for synthesis of the target enzymes in the fungus. The aim of this study was to screen Candida spp. resistant to fluconazole for the expression of ERG11 gene. Fluconazole susceptibility test was performed on 28 clinical strains of Candida species previously obtained from students of a School of Nursing in Lagos, Nigeria. They were identified by API Candida, CHROMagar candida and germ tube test. Using 25 mcg discs, fluconazole susceptibility was determined by the disc diffusion method and results were interpreted in accordance with the Clinical Laboratory Standard Institute (CLSI) criteria; sensitive (S), resistant (R) and susceptible dose dependent (SDD). The R and SDD isolates were subsequently evaluated for the presence of ERG11 gene. Of the 28 clinical isolates, 14 were identified as C. albicans and six as C. tropicalis. The remaining isolates were identified as C. glabrata (2), C. famata (2) C. kefyr (2) one each of C. parapsilosis and C. guilliermondii respectively. In this study, 18 were susceptible (S) to fluconazole, eight were SDD and two were resistant to the antifungal agent. Out of the 14 C. albicans isolates, 12 were susceptible, one showed high level resistance and similar number showed susceptible dose dependence. ERG11 was detected in three susceptible dose dependent Candida species. This analysis demonstrates that susceptible dose dependence should not be overlooked as it may be associated with the presence of ERG11 gene and resistance to fluconazole. There is a need to consider routine antifungal susceptibility testing for Candida species causing vulvovaginitis.

Entities:  

Keywords:  Candida species; ERG11 gene; Fluconazole; antifungal susceptibility

Year:  2012        PMID: 22493755      PMCID: PMC3316451     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  19 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Authors:  Cornelius J Clancy; Victor L Yu; Arthur J Morris; David R Snydman; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Lysis of viable yeast cells by enzymes of Arthrobacter luteus.

Authors:  K Kitamura; T Kaneko; Y Yamamoto
Journal:  Arch Biochem Biophys       Date:  1971-07       Impact factor: 4.013

Review 5.  Candidal vulvovaginitis.

Authors:  J D Sobel
Journal:  Clin Obstet Gynecol       Date:  1993-03       Impact factor: 2.190

Review 6.  Molecular genetic analysis of azole antifungal mode of action.

Authors:  S L Kelly; A Arnoldi; D E Kelly
Journal:  Biochem Soc Trans       Date:  1993-11       Impact factor: 5.407

7.  Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.

Authors:  C A Enwuru; A Ogunledun; N Idika; N V Enwuru; F Ogbonna; M Aniedobe; A Adeiga
Journal:  Afr Health Sci       Date:  2008-09       Impact factor: 0.927

8.  Molecular differentiation and antifungal susceptibility of Candida albicans isolated from patients with respiratory infections in Guiyang Medical College Hospital, China.

Authors:  Ying Liu; Yingqian Kang; Koji Yokoyama; Tohru Gonoi; Yuzuru Mikami
Journal:  Nihon Ishinkin Gakkai Zasshi       Date:  2009

Review 9.  History of the development of azole derivatives.

Authors:  J A Maertens
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

10.  Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Authors:  Suzanne E Ohmit; Jack D Sobel; Paula Schuman; Ann Duerr; Kenneth Mayer; Anne Rompalo; Robert S Klein
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

View more
  9 in total

1.  A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans.

Authors:  Arome Solomon Odiba; Olanrewaju Ayodeji Durojaye; Ifeoma Maureen Ezeonu; Anthony Christian Mgbeahuruike; Bennett Chima Nwanguma
Journal:  Infect Drug Resist       Date:  2022-06-17       Impact factor: 4.177

2.  The yeast anaerobic response element AR1b regulates aerobic antifungal drug-dependent sterol gene expression.

Authors:  Christina Gallo-Ebert; Melissa Donigan; Hsing-Yin Liu; Florencia Pascual; Melissa Manners; Devanshi Pandya; Robert Swanson; Denise Gallagher; Weiwei Chen; George M Carman; Joseph T Nickels
Journal:  J Biol Chem       Date:  2013-10-25       Impact factor: 5.157

Review 3.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

4.  Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran.

Authors:  F Katiraee; F Teifoori; M Soltani
Journal:  Curr Med Mycol       Date:  2015-09

Review 5.  Candidiasis and Mechanisms of Antifungal Resistance.

Authors:  Somanon Bhattacharya; Sutthichai Sae-Tia; Bettina C Fries
Journal:  Antibiotics (Basel)       Date:  2020-06-09

6.  Antifungal Activity of ZnO Nanoparticles and Nystatin and Downregulation of SAP1-3 Genes Expression in Fluconazole-Resistant Candida albicans Isolates from Vulvovaginal Candidiasis.

Authors:  Seyededeh Sedigheh Hosseini; Hamidreza Joshaghani; Tahereh Shokohi; Alireza Ahmadi; Zahra Mehrbakhsh
Journal:  Infect Drug Resist       Date:  2020-02-13       Impact factor: 4.003

7.  Investigation of the Defective Growth Pattern and Multidrug Resistance in a Clinical Isolate of Candida glabrata Using Whole-Genome Sequencing and Computational Biology Applications.

Authors:  Osman Merdan; Ayşe Sena Şişman; Seçil Ak Aksoy; Samet Kızıl; Nazmiye Ülkü Tüzemen; Emel Yılmaz; Beyza Ener
Journal:  Microbiol Spectr       Date:  2022-07-18

8.  Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence.

Authors:  Rita O Oladele; Alani S Akanmu; Augustina O Nwosu; Folasade T Ogunsola; Malcolm D Richardson; David W Denning
Journal:  Open Forum Infect Dis       Date:  2016-03-15       Impact factor: 3.835

9.  Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.

Authors:  Sayanika Devi Waikhom; Innocent Afeke; Grace Sefakor Kwawu; Hintermann Kobina Mbroh; George Yiadom Osei; Bengyella Louis; John Gameli Deku; Emmanuel Senyo Kasu; Prosper Mensah; Charles Yao Agede; Cornelius Dodoo; Emmanuel Akomanin Asiamah; John Tampuori; John Korbuvi; Japheth Awuletey Opintan
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-06       Impact factor: 3.007

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.